21-May-2025 3:00 PM CST - Business Wire Arcellx Announces Its Participation at TD Cowens 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced two upcoming investor events: TD Cowens 6th Annual Oncology Innovation Summit Tuesday, May 27, 2025 at 9:00 a.m. PT (Virtual) Management and Physician Presentation and Discussion of iMMagine-1 Pivotal Study Results During EHA2025 Friday, June 13, 2025 at
8-May-2025 3:00 PM CST - Business Wire Arcellx Provides First Quarter 2025 Financial Results and Business Highlights Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first quarter ended March 31, 2025. Delivering therapies that can positively impact patients lives is our mission, said Rami Elghandour, Arcellxs Chairman and Chief Executive Officer. We are pleased tha
27-Feb-2025 3:00 PM CST - Business Wire Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2024. 2024 was a transformational year for Arcellx as our ASH data presentations for anito-cel, in partnership with Kite, continued to demonstrate anito-cels diff
26-Feb-2025 3:00 PM CST - Business Wire Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, at 1:10 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Investors s
7-Nov-2024 3:00 PM CST - Business Wire Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported financial results for the third quarter ended September 30, 2024, and provided recent business highlights. We believe the data from the recently published ASH abstracts continues to differentiate anito-cels clinical profile as a potentially best-in-class
21-May-2025 3:00 PM CST - Business Wire Arcellx Announces Its Participation at TD Cowens 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced two upcoming investor events: TD Cowens 6th Annual Oncology Innovation Summit Tuesday, May 27, 2025 at 9:00 a.m. PT (Virtual) Management and Physician Presentation and Discussion of iMMagine-1 Pivotal Study Results During EHA2025 Friday, June 13, 2025 at
8-May-2025 3:00 PM CST - Business Wire Arcellx Provides First Quarter 2025 Financial Results and Business Highlights Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first quarter ended March 31, 2025. Delivering therapies that can positively impact patients lives is our mission, said Rami Elghandour, Arcellxs Chairman and Chief Executive Officer. We are pleased tha
27-Feb-2025 3:00 PM CST - Business Wire Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2024. 2024 was a transformational year for Arcellx as our ASH data presentations for anito-cel, in partnership with Kite, continued to demonstrate anito-cels diff
26-Feb-2025 3:00 PM CST - Business Wire Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, at 1:10 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Investors s
7-Nov-2024 3:00 PM CST - Business Wire Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported financial results for the third quarter ended September 30, 2024, and provided recent business highlights. We believe the data from the recently published ASH abstracts continues to differentiate anito-cels clinical profile as a potentially best-in-class
